Patients with thrombotic antiphospholipid syndrome are better treated with a vitamin K antagonist, such as warfarin, rather than a direct oral anticoagulant (DOAC), a new systematic review and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results